SCHEMBL4135587

SCHEMBL4135587

CN(C)CCNc1ccc(C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
CYP1A2 P05177 1/20 0.51
MAOA P21397 1/20 0.51
CNR1 P21554 1/20 0.51
DRD4 P21917 1/20 0.51
ACHE P22303 1/20 0.51
HRH2 P25021 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
MAPK1 P28482 1/20 0.51
NTSR1 P30989 1/20 0.51
HRH1 P35367 1/20 0.51
DRD3 P35462 1/20 0.51
SCN1A P35498 1/20 0.51
HTR2B P41595 1/20 0.51
SCN7A Q01118 1/20 0.51
SLC6A3 Q01959 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN5A Q14524 1/20 0.51
SCN9A Q15858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5071263 0.98 LMNA (0.52) LMNACYP1A2MAOACNR1DRD4
SCHEMBL3689477 0.86 LMNA (0.51) LMNACYP1A2MAOACNR1DRD4
SCHEMBL5724876 0.85 ALDH1A1 (0.51) LMNACYP1A2MAOACNR1DRD4
SCHEMBL14558203 0.83 POLB (0.42) LMNACYP1A2MAOACNR1DRD4
SCHEMBL64206 0.83 POLB (0.64) LMNACYP1A2MAOACNR1DRD4
SCHEMBL9294324 0.83 ALDH1A1 (0.52) LMNAACHEMAPK1KCNH2SIGMAR1
SCHEMBL872409 0.79 HCAR3 (0.57) LMNACYP1A2MAOACNR1DRD4
SCHEMBL5067501 0.79 LMNA (0.67) LMNACYP1A2MAOACNR1DRD4
SCHEMBL11639378 0.79 LMNA (0.49) LMNACYP1A2MAOACNR1DRD4
SCHEMBL11748691 0.79 PRSS1 (0.57) POLBTP53TSHRMITFALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 US disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 US disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 US disclosed
EP-4066896-A1 G9A INHIBITOR RIKEN (JP) 2022-10-05 EP disclosed
WO-2021106988-A1 G9a INHIBITOR 杏林製薬株式会社 2021-06-03 WO disclosed
EP-2013196-A2 DISUBSTITUTED ANILINE COMPOUNDS Merck & Co., Inc. (US) 2009-01-14 EP disclosed
WO-2007127137-A2 DISUBSTITUTED ANILINE COMPOUNDS MERCK & CO., INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127046-A1 G9a INHIBITOR EZH2, BMI1, DOT1L LMNA 1143/4885CYP1A2 4357/4885MAOA 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.